Literature DB >> 3118192

Structural significance of the GTP-binding domain of ras p21 studied by site-directed mutagenesis.

D J Clanton1, Y Y Lu, D G Blair, T Y Shih.   

Abstract

Point mutations of p21 proteins were constructed by oligonucleotide-directed mutagenesis of the v-rasH oncogene, which substituted amino acid residues within the nucleotide-binding consensus sequence, GXG GXGK. When the glycine residue at position 10, 13, or 15 was substituted with valine, the viral rasH product p21 lost its GTP-binding and autokinase activities. Other substitutions at position 33, 51, or 59 did not impair its binding activity. G418-resistant NIH 3T3 cell lines were derived by transfection with constructs obtained by inserting the mutant proviral DNA into the pSV2neo plasmid. Clones with a valine mutation at position 13 or 15 were incapable of transforming cells, while all other mutants with GTP-binding activity were competent. A mutant with a substitution of valine for glycine at position 10 which had lost its ability to bind GTP and its autokinase activity was fully capable of transforming NIH 3T3 cells. These cells grew in soft agar and rapidly formed tumors in nude mice. The p21 of cell lines derived from tumor explants still lacked the autokinase activity. These findings suggest that the glycine-rich consensus sequence is important in controlling p21 activities and that certain mutations may confer to p21 its active conformation without participation of ligand binding.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118192      PMCID: PMC367941          DOI: 10.1128/mcb.7.9.3092-3097.1987

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  33 in total

Review 1.  Oncogenes and cancer: the p21 ras genes.

Authors:  T Y Shih; M O Weeks
Journal:  Cancer Invest       Date:  1984       Impact factor: 2.176

2.  Predicted nucleotide-binding properties of p21 protein and its cancer-associated variant.

Authors:  R K Wierenga; W G Hol
Journal:  Nature       Date:  1983-04-28       Impact factor: 49.962

3.  Functional organization of the Harvey murine sarcoma virus genome.

Authors:  E H Chang; J M Maryak; C M Wei; T Y Shih; R Shober; H L Cheung; R W Ellis; G L Hager; E M Scolnick; D R Lowy
Journal:  J Virol       Date:  1980-07       Impact factor: 5.103

4.  Comparative biochemical properties of normal and activated human ras p21 protein.

Authors:  J P McGrath; D J Capon; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

5.  The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity.

Authors:  R W Sweet; S Yokoyama; T Kamata; J R Feramisco; M Rosenberg; M Gross
Journal:  Nature       Date:  1984 Sep 20-26       Impact factor: 49.962

6.  Characterization of the phosphorylation sites and the surrounding amino acid sequences of the p21 transforming proteins coded for by the Harvey and Kirsten strains of murine sarcoma viruses.

Authors:  T Y Shih; P E Stokes; G W Smythers; R Dhar; S Oroszlan
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

7.  Autophosphorylation of v-Ha-ras p21 is modulated by amino acid residue 12.

Authors:  J B Gibbs; R W Ellis; E M Scolnick
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

8.  Activation of ras genes in human tumors does not affect localization, modification, or nucleotide binding properties of p21.

Authors:  T Finkel; C J Der; G M Cooper
Journal:  Cell       Date:  1984-05       Impact factor: 41.582

9.  High-level expression in Escherichia coli of enzymatically active Harvey murine sarcoma virus p21ras protein.

Authors:  J A Lautenberger; L Ulsh; T Y Shih; T S Papas
Journal:  Science       Date:  1983-08-26       Impact factor: 47.728

10.  Neutralizing monoclonal antibody against ras oncogene product p21 which impairs guanine nucleotide exchange.

Authors:  S Hattori; D J Clanton; T Satoh; S Nakamura; Y Kaziro; M Kawakita; T Y Shih
Journal:  Mol Cell Biol       Date:  1987-05       Impact factor: 4.272

View more
  15 in total

1.  Conformational effects of amino acid substitutions at positions 10, 12, and 13 in the P21 protein.

Authors:  P W Brandt-Rauf; M R Pincus; R P Carty; J Lubowsky; M Avitable; H F Kung; J Maizel
Journal:  J Protein Chem       Date:  1989-02

Review 2.  The biochemistry of ras p21.

Authors:  R J Grand; D Owen
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

3.  Structural effects of the binding of GTP to the wild-type and oncogenic forms of the ras-gene-encoded p21 proteins.

Authors:  R Monaco; J M Chen; F K Friedman; P Brandt-Rauf; D Chung; M R Pincus
Journal:  J Protein Chem       Date:  1995-11

4.  Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins.

Authors:  L A Feig; G M Cooper
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

5.  Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP.

Authors:  L A Feig; G M Cooper
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

6.  Comparison of the computed three-dimensional structures of oncogenic forms (bound to GDP) of the ras-gene-encoded p21 protein with the structure of the normal (non-transforming) wild-type protein.

Authors:  R Monaco; J M Chen; D Chung; P Brandt-Rauf; M R Pincus
Journal:  J Protein Chem       Date:  1995-08

7.  Comparison of the low energy conformations of an oncogenic and a non-oncogenic p21 protein, neither of which binds GTP or GDP.

Authors:  A Liwo; K D Gibson; H A Scheraga; P W Brandt-Rauf; R Monaco; M R Pincus
Journal:  J Protein Chem       Date:  1994-02

8.  Negative regulation of Raf-1 by phosphorylation of serine 621.

Authors:  H Mischak; T Seitz; P Janosch; M Eulitz; H Steen; M Schellerer; A Philipp; W Kolch
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

9.  Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer.

Authors:  Wilbur B Bowne; Josef Michl; Martin H Bluth; Michael E Zenilman; Matthew R Pincus
Journal:  Cancer Ther       Date:  2007

10.  Mammalian assay for site-specific DNA damage processing using the human H-ras proto-oncogene.

Authors:  L Arcangeli; K J Williams
Journal:  Nucleic Acids Res       Date:  1995-06-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.